Jason M. Broderick | Authors


18F-DCFPyL, PSMA-Targeted PET Imaging Agent, Provokes High CLR and PPV

February 13, 2021

Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.

Clinically Meaningful Activity Observed With Combination Cabozantinib and Atezolizumab in mCRPC

May 31, 2020

According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.